NCT07583212RecruitingPhase 1
An Open-Label, Multicenter Phase I Study on the Safety, Tolerability, Pharmacokinetics and Efficacy of HRS-1635 in Patients With B-Cell Malignancies.
Chengdu Suncadia Medicine Co., Ltd.1 site in 1 country180 target enrollmentStarted: June 30, 2026Last updated:
Interventions
Trial Snapshot
- Phase
- Phase 1
- Status
- Recruiting
- Enrollment
- 180
- Locations
- 1
Study Overview
Brief Summary
The study is being conducted to evaluate the safety and tolerability of HRS-1635. To observe the Dose-Limiting Toxicity (DLT) , explore the Maximum Tolerated Dose (MTD, if possible) and the Recommended Phase 2 Dose (RP2D). This study also preliminarily evaluated the efficacy of HRS-1635 in participants with B-cell malignancy.
Study Design
- Study Type
- Interventional
- Allocation
- Na
- Intervention Model
- Single Group
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Age ≥ 18 years old;
- •Eastern Cooperative Oncology Group (ECOG) performance status score of 0-1;
- •Expected survival time ≥ 12 weeks;
- •Histologically or cytologically confirmed relapsed/refractory B-cell malignant tumor;
- •Females of childbearing potential and male participants whose partners are females of childbearing potential must agree to adopt adequate and effective contraceptive measures during the study period. Female participants must not be breastfeeding;
- •Participants voluntarily enroll in the study, sign the informed consent form, with good compliance and willingness to cooperate with follow-up procedures.
Exclusion Criteria
- •Tumor infiltration of the central nervous system;
- •A history of other malignant tumors (excluding the study disease) within 2 years prior to the first administration of the study drug;
- •A history of allogeneic hematopoietic stem cell transplantation or solid organ transplantation;
- •Positive for hepatitis B surface antigen (HBsAg) at screening with evidence of viral replication confirmed by HBV-DNA test;
- •Positive for hepatitis C virus antibody (HCV-Ab) at screening with evidence of viral replication confirmed by HCV-RNA test;
- •Positive for human immunodeficiency virus (HIV) antigen/antibody test at screening;
- •History of major surgery or severe trauma within 28 days prior to the first administration of the study drug;
- •Presence of severe cardiovascular disease.;
- •Persistent alcohol or drug abuse;
- •Inability to take oral medication, or presence of severe gastrointestinal dysfunctional diseases, or history of surgery with severe impact on gastrointestinal function.
- •Pregnant or lactating females.
- •Concurrent participation in other interventional clinical trials, or an interval of less than 1 month between the signing date of the informed consent form and the last administration of the study drug in the previous clinical trial;
Arms & Interventions
HRS-1635
Experimental
Intervention: HRS-1635 (Drug)
Investigators
Study Sites (1)
Loading locations...
Similar Trials
Completed
Not Applicable
Safety Evaluation of HORS-051511 in Healthy AdultsCTRI/2023/12/060476Himalaya Wellness Company (HWC)12
Recruiting
Phase 1
A Study of SHR-4375 Injection in Combination With Other Antitumor Therapies in Patients With Solid TumorsNCT07298772Suzhou Suncadia Biopharmaceuticals Co., Ltd.198
Unknown
Phase 1
健康受试者单次静脉或皮下给予 SHR-2106 后的安全性、耐受性、药代动力学和药效学 I 期临床研究ChiCTR2300073564广东恒瑞医药有限公司
Recruiting
Phase 2
Anifrolumab in Adults With Primary Antiphospholipid Syndrome (AnifAPS Trial)NCT07584083National and Kapodistrian University of Athens20
Unknown
Phase 1
HRS-2129 在健康受试者中单次给药的安全性、耐受性、药代动力学、药效动力学及食物影响研究ChiCTR2400092301山东盛迪医药有限公司 / 上海恒瑞医药有限公司